Industry News
Excerpt from the Press Release: NEWTON, Mass.–(BUSINESS WIRE)–ClearB Therapeutics, Inc., a clinical-stage biotechnology company committed to developing therapies to drive functional cure in patients with chronic hepatitis B (CHB) infection, announced that review of the safety data from the sentinel subject supported enrollment for the remainder of the cohort in their Phase 1b clinical study…
Read More
Overcoming limitations of traditional assay enables definitive diagnosis, refinement of prognosis and opportunities for optimized treatment Excerpt from the Press Release: CARLSBAD, Calif.–(BUSINESS WIRE)–Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced the publication of a study from investigators at Johns Hopkins University showing…
Read More
The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at the Precision in Clinical Trials Summit in San Diego, CA. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing imaging based research and streamlining clinical trial execution for Sponsors and CROs. Meet with…
Read More
The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at the Clinical Outsourcing Group Bay Area in San Francisco, CA. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing imaging based research and streamlining clinical trial execution for Sponsors and CROs. Meet with…
Read More
Excerpt from the Press Release: PHILADELPHIA, Oct. 2, 2025 /PRNewswire/ — Verismo Therapeutics, a clinical-stage CAR T company developing novel KIR-CAR platform technology, today announced that it has treated the first patient with follicular lymphoma (FL) in its CELESTIAL-301 Phase 1 clinical trial of SynKIR™-310. This milestone reflects Verismo’s commitment to addressing the urgent unmet medical…
Read More
evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in ITT and ESR1-mutated populations in the post-CDK inhibitor setting, compared with standard of care plus everolimus The all-oral combination was well tolerated and adverse events were consistent with the known safety profiles of the individual study treatments; no new safety signals were observed evERA…
Read More
The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at the Annual SoCalBio Investor & Partnering Conference in Newport Beach, CA. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing imaging based research and streamlining clinical trial execution for Sponsors and CROs. Meet…
Read More
The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at SCDM in Baltimore. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing imaging based research and streamlining clinical trial execution for Sponsors and CROs. Meet with Chris Hamelin, Christopher Kata and Nick Travers…
Read More
How TrialStat’s Quarterly Releases Deliver Real Value to Sponsors, CROs, and Sites In today’s fast-paced clinical research environment, flexibility and responsiveness aren’t just nice-to-haves-they’re mission-critical. At TrialStat, our commitment to quarterly platform releases is rooted in one goal: to empower our clients with a nimble, innovative, and responsive technology ecosystem that grows with their needs.…
Read More
The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at the COG CRO Summit in Amsterdam. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing imaging based research and streamlining clinical trial execution for Sponsors and CROs. Meet with Chris Hamelin and Nick…
Read More